- Home
- NRG vs DGX Comparison
NRG vs DGX Comparison
Compare NRG & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRG | DGX |
|---|---|---|
| Founded | 1989 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 23.2B |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NRG | DGX |
|---|---|---|
| Price | $123.06 | $236.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $203.00 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 3.0M | 1.0M |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | 1.27% | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 2.84 | ★ 5.08 |
| Revenue | ★ $30,713,000,000.00 | $11,035,000,000.00 |
| Revenue This Year | $14.46 | $7.53 |
| Revenue Next Year | $3.12 | $3.77 |
| P/E Ratio | ★ $44.45 | $46.14 |
| Revenue Growth | 9.18 | ★ 11.78 |
| 52 Week Low | $112.50 | $171.18 |
| 52 Week High | $189.96 | $240.13 |
Technical Indicators
Market Signals| Indicator | NRG | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 66.64 |
| Support Level | $112.50 | $187.73 |
| Resistance Level | $145.74 | $240.13 |
| Average True Range (ATR) | 7.07 | 4.25 |
| MACD | -0.04 | -0.78 |
| Stochastic Oscillator | 36.09 | 66.97 |
Price Performance
Historical ComparisonAbout NRG NRG Energy Inc.
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 26 gigawatts of coal, gas, and oil power generation capacity in Texas and the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.